• Explore /
  • Poster
  • / Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC).

Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC).

Abstract Video & Slides Poster

Authors

null

Rachel N. Grisham

Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

Rachel N. Grisham , Ignace Vergote , Susana N. Banerjee , Esther N. Drill , Michel Fabbro , Mansoor Raza Mirza , Ignacio Romero , Robert L. Coleman , Amit M. Oza , Felix Hilpert , Kathleen N. Moore , Anneke M. Westermann , Carol Aghajanian , Giovanni Scambia , Adam P. Boyd , Jean Cantey-Kiser , David M. O'Malley , John H. Farley , Nicoletta Colombo , Bradley J. Monk

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT01849874

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 5519)

DOI

10.1200/JCO.2021.39.15_suppl.5519

Abstract #

5519

Abstract Disclosures

Similar Posters

First Author: Bradley J. Monk

First Author: Bradley J. Monk

First Author: Ardaman Shergill

First Author: Matthew Dankner